Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioXcel Therapeutics (BTAI) Operating Expenses (2022 - 2025)

BioXcel Therapeutics has reported Operating Expenses over the past 4 years, most recently at $10.5 million for Q4 2025.

  • Quarterly results put Operating Expenses at $10.5 million for Q4 2025, down 2.96% from a year ago — trailing twelve months through Dec 2025 was $51.1 million (down 26.48% YoY), and the annual figure for FY2025 was $51.1 million, down 26.48%.
  • Operating Expenses for Q4 2025 was $10.5 million at BioXcel Therapeutics, down from $14.3 million in the prior quarter.
  • Over the last five years, Operating Expenses for BTAI hit a ceiling of $53.1 million in Q4 2022 and a floor of $10.3 million in Q1 2025.
  • Median Operating Expenses over the past 4 years was $22.5 million (2023), compared with a mean of $28.4 million.
  • Biggest five-year swings in Operating Expenses: soared 63.29% in 2023 and later tumbled 68.12% in 2024.
  • BioXcel Therapeutics' Operating Expenses stood at $53.1 million in 2022, then tumbled by 61.89% to $20.3 million in 2023, then plummeted by 46.38% to $10.9 million in 2024, then fell by 2.96% to $10.5 million in 2025.
  • The last three reported values for Operating Expenses were $10.5 million (Q4 2025), $14.3 million (Q3 2025), and $16.0 million (Q2 2025) per Business Quant data.